Therapy Areas: AIDS & HIV
Sylvant Recommended by the National Comprehensive Cancer Network as the Preferred Treatment Option for Patients with Idiopathic Multicentric Castleman Disease Regardless of Histopathologic Subtype
25 February 2021 - - The US-based National Comprehensive Cancer Network (NCCN) has updated their Clinical Practice Guidelines in Oncology (NCCN Guidelines) for B-Cell Lymphomas to include siltuxi...
AHF announces 3m COVID-19 vaccine production by April to bring the pandemic under control
25 February 2021 - AIDS Healthcare Foundation (AHF) reported on Wednesday that the US will have 3m vaccine doses per day available by April in the fight against the COVID-19 variants.In conjunction, t...
New COVID-19 virus variant discovered in New York City and Northeast US
25 February 2021 - CNN reported on Thursday that two separate teams of researchers have said this week that they have found a worrying new COVID-19 virus variant in New York City and elsewhere in the ...
ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Expanded Use of Cabenuva as an HIV Treatment for Use Every 2-Months
24 February 2021 - - US-based specialist HIV company ViiV Healthcare has submitted a supplemental New Drug Application to the US Food and Drug Administration for the expanded use of Cabenuva (cabotegr...
BioMarin names new director
19 February 2021 - It was reported on Thursday that United States-based BioMarin has named Maykin Ho, PhD, as its new director.Dr Ho has over 30 years of experience in the healthcare and finance indus...
Sagent Pharmaceuticals adds Camostat mesilate to ACTIV-2 Adaptive Platform Treatment Trial for COVID-19
15 February 2021 - Sagent Pharmaceuticals, a Nichi-Iko Group Company, announced on Friday that Camostat mesilate (Camostat) has been added to the present ACTIV-2 Adaptive Platform Treatment Trial inte...